The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV;Surcoût du passage de l'Option B à l'Option B+ pour la prévention de la transmission du VIH de la mère à l'enfant

Bulletin of the World Health Organization

Volumn 92, Issue 3, 2014, Pages 162-170

  O'Brien, Lisa ^a   Shaffer, Nathan ^b   Sangrujee, Nalinee ^a   Abimbola, Taiwo O ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; TENOFOVIR;

ARTICLE; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DISEASE TRANSMISSION; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOTHER TO CHILD TRANSMISSION; PREGNANCY; PREVENTION AND CONTROL; PROSPECTIVE STUDY;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84896889131     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.13.122523     Document Type: Article

References (29)

1. Global AIDS response progress reporting 2013: construction of core indicators for monitoring the 2011 UN political declaration on HIV/AIDS. Geneva: Joint United Nations Programme on HIV/AIDS; 2013. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/document/2013/GARPR_2013_guidelines_en.pdf [accessed 10 October 2013].
2. 2013 progress report on the global plan: towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive. Geneva: Joint United Nations Programme on HIV/AIDS; 2013. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2013/20130625_progress_global_plan_en.pdf [accessed 10 October 2013].
3. 2013 Global UNAIDS Factsheet [Internet]. Geneva: Joint United Nations Programme on HIV/AIDS; 2013. Available from: http://www.unaids.org/en/resources/campaigns/globalreport2013/factsheet/ [accessed 10 December 2013].
4. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach. 2010 revision. Geneva: World Health Organization; 2010.
5. Consolidated guidelines on general HIV care and the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013.
6. Programmatic update: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: executive summary, April 2012. Geneva: World Health Organization; 2012. Available from: http://www.who.int/hiv/PMTCT_update.pdf [accessed 10 October 2013].
7. Fasawe O, Avila C, Shaffer N, Schouten E, Chimbwandira F, Hoos D et al. Cost-effectiveness analysis of OptionB+ for HIV prevention and treatment of mothers and children in Malawi. PLoS One 2013;8:e57778. doi: http://dx.doi.org/10.1371/journal.pone.0057778 PMID:23554867
8. Kesho Bora Study Group. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011;11:171-80. doi: http://dx.doi.org/10.1016/S1473-3099(10)70288-7 PMID:21237718
9. Coovadia HM, Brown ER, Fowler MG, Chipato T, Moodley D, Manji K et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Lancet 2012;379:221-8. doi: http://dx.doi.org/10.1016/S0140-6736(11)61653-X PMID:22196945
10. Chasela CS, Hudgens MG, Jamieson DJ, Kayira D, Hosseinipour MC, Kourtis AP et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010;362:2271-81. doi: http://dx.doi.org/10.1056/NEJMoa0911486 PMID:20554982
11. Jamieson DJ, Chasela CS, Hudgens MG, King CC, Kourtis AP, Kayira D et al. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. Lancet 2012;379:2449-58. doi: http://dx.doi.org/10.1016/S0140-6736(12)60321-3 PMID:22541418
12. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505. doi: http://dx.doi.org/10.1056/NEJMoa1105243 PMID:21767103
13. The Interagency Task Team on the Prevention and Treatment of HIV Infection in Pregnant Women, Mothers and Children. Mothers and children: monitoring progress towards PMTCT goals. New York: IATT; 2012. Available from: http://www.emtct-iatt.org/ [accessed 13 September 2013].
14. Global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive 2011-2015. Geneva: Joint United Nations Programme on HIV/AIDS; 2011. [accessed 10 October 2013].
15. Resolution A/RES/55/2. Resolution adopted by the General Assembly: 55/2. United Nations Millennium Declaration. In: Fifty-fifth General Assembly of the United Nations, New York, 18 September 2000. Research guides & resources. New York: United Nations; 2000. Available from: http://www.un.org/en/ga/search/view_doc.asp?symbol=A/RES/55/2&Lang=E [accessed 6 December 2013].
16. Menzies NA, Berruti AA, Berzon R, Filler S, Ferris R, Ellerbrock TV et al. The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS 2011;25:1753-60. doi: http://dx.doi.org/10.1097/QAD.0b013e3283463eec PMID:21412127
17. WHO Global Price Reporting Mechanism [Internet]. Geneva: World Health Organization; 2011. Available from: http://apps.who.int/hiv/amds/price/hdd/ [accessed 18 March 2013].
18. Otieno PA, Brown ER, Mbori-Ngacha DA, Nduati RW, Farquhar C, Obimbo EM et al. HIV-1 disease progression in breast-feeding and formula-feeding mothers: a prospective 2-year comparison of T cell subsets, HIV-1 RNA levels, and mortality. J Infect Dis 2007;195:220-9. doi: http://dx.doi.org/10.1086/510245 PMID:17191167
19. Ekouevi D, Abrams EJ, Schlesinger M, Myer L, Phanuphak N, Carter RJ et al. Maternal CD4+ cell count decline after interruption of antiretroviral prophylaxis for the prevention of mother-to-child transmission of HIV. PLoS One 2012;7:e43750. doi: http://dx.doi.org/10.1371/journal.pone.0043750 PMID:22952754
20. Carter RJ, Dugan K, El-Sadr WM, Myer L, Otieno J, Pungpapong N et al. CD4+ cell count testing more effective than HIV disease clinical staging in identifying pregnant and postpartum women eligible for antiretroviral therapy in resource-limited settings. J Acquir Immune Defic Syndr 2010;55:404-10. doi: http://dx.doi.org/10.1097/QAI.0b013e3181e73f4b PMID:20595905
21. Turan JM, Steinfeld RL, Onono M, Bukusi EA, Woods M, Shade SB et al. The study of HIV and antenatal care integration in pregnancy in Kenya: design, methods, and baseline results of a cluster-randomized controlled trial. PLoS One 2012;7:e44181. doi: http://dx.doi.org/10.1371/journal.pone.0044181 PMID:22970177
22. Guidelines on HIV and infant feeding 2010: principles and recommendations for infant feeding in the context of HIV and a summary of evidence. Geneva: World Health Organization; 2010.
23. Bureau of Labor Statistics [Internet]. Consumer Price Index 2009-2011. Washington: BLS, United States Department of Labor; 2013. Available from: http://www.bls.gov/cpi/data.htm [accessed 10 October 2013].
24. Untangling the web of antiretroviral price reductions [Internet]. Geneva: Médecins Sans Frontières; 2013. Available from: http://utw.msfaccess.org/ [accessed 10 December 2013].
25. Hamers RL, Sigaloff KCE, Wensing AM, Wallis CL, Kityo C, Siwale M et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis 2012;54:1660-9. doi: http://dx.doi.org/10.1093/cid/cis254 PMID:22474222
26. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 2004;292:224-36. doi: http://dx.doi.org/10.1001/jama.292.2.224 PMID:15249572
27. Mayer K, Wang L, Hoffman I, McCauley M, Li X, Safren S et al. Sustained treatment as prevention: continued decreases in unprotected sex and increases in virological suppression after HAART initiation among participants in HPTN 052. In: Proceedings of the XIX International AIDS Conference; 22-27 July 2012; Washington. Geneva: AIDS 2012 Secretariat; 2012.
28. Ciaranello AL, Perez F, Engelsmann B, Walensky RP, Mushavi A, Rusibamayila A et al. Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe. Clin Infect Dis 2013;56:430-46. doi: http://dx.doi.org/10.1093/cid/cis858 PMID:23204035
29. Binagwaho A, Pegurri E, Drobac PC, Mugwaneza P, Stulac SN, Wagner CM et al. Prevention of mother-to-child transmission of HIV: cost-effectiveness of antiretroviral regimens and feeding options in Rwanda. PLoS One 2013;8:e54180. doi: http://dx.doi.org/10.1371/journal.pone.0054180 PMID:23437040